Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Given Consensus Rating of “Hold” by Analysts

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have been assigned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $3.75.

HOWL has been the topic of a number of research analyst reports. Weiss Ratings lowered Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th.

Werewolf Therapeutics Price Performance

Shares of HOWL stock opened at $0.37 on Friday. Werewolf Therapeutics has a 12-month low of $0.27 and a 12-month high of $2.38. The firm has a market capitalization of $17.88 million, a price-to-earnings ratio of -0.30 and a beta of 0.30. The business has a 50 day simple moving average of $0.41 and a 200 day simple moving average of $0.62.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. On average, equities analysts anticipate that Werewolf Therapeutics will post -1.08 EPS for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total value of $145,918.85. Following the completion of the sale, the insider owned 303,719 shares in the company, valued at $106,301.65. This represents a 57.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Luke Evnin sold 107,429 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $0.31, for a total transaction of $33,302.99. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 4,067,237 shares of company stock valued at $2,070,189. Company insiders own 23.60% of the company’s stock.

Institutional Trading of Werewolf Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of HOWL. Regal Investment Advisors LLC grew its holdings in shares of Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after buying an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. lifted its stake in Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in Werewolf Therapeutics in the 2nd quarter worth about $48,000. AQR Capital Management LLC acquired a new stake in Werewolf Therapeutics during the 1st quarter worth about $79,000. Finally, Bridgeway Capital Management LLC boosted its position in Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares during the period. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.